Immuno-Oncology Veteran Rachel Humphrey Joins CytomX
This article was originally published in Scrip
Executive Summary
CytomX Therapeutics, Inc., a biopharmaceutical company developing therapeutics for the treatment of cancer, has appointed Dr. Rachel Humphrey chief medical officer. Humphrey formerly led immuno-oncology at Eli Lilly and AstraZeneca; oversaw clinical development of Yervoy (ipilmumab), the first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb; and played a role in the development of Nexavar (sorafenib) at Bayer. She was also previously a member of CytomX's board of directors.
You may also be interested in...
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
Bristol-Myers Squibb expanded its collaboration with CytomX for $200m up front and up to $3.6bn in milestone fees. Also, Takeda spun out eight non-core molecules into a new joint venture and X-Chem executed two deals with Japanese partners, among other recent deals.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.